READING, England--(BUSINESS WIRE)--FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants. Published in the New England Journal of Medicine, results from this trial demonstrate for the first time that a single dose monoclonal antibody can significantly reduce medically attended RSV LRTI in infants through the average temperate region RSV season (November-March).1
“The data for nirsevimab are exciting, as they highlight the potential for this innovative approach to protect infants from RSV with just one injection for the entire season,” said Dr. Joseph Domachowske, study author, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University. “Nirsevimab offers the important potential to reduce hospitalisations and emergency department and in-office visits, which are a significant burden for healthcare systems.”
Nirsevimab is an extended half-life RSV monoclonal antibody (mAb), being developed in partnership with AstraZeneca as a passive immunisation, meaning a protective antibody is administered directly to an infant to help prevent RSV.
Phase 2b trial met primary and secondary endpoints
On the primary endpoint, nirsevimab achieved a statistically significant 70.1% (95% CI: 52.3%-81.2%) reduction of medically attended RSV LRTI compared to placebo through 150 days post-dose. On the secondary endpoint, nirsevimab achieved a 78.4% (95% CI: 51.9%-90.3%) relative reduction in the incidence of hospitalisations due to RSV LRTI compared to placebo through 150 days post-dose. Nirsevimab was found to be tolerable based on types and frequencies of treatment emergent adverse events.1
“It’s encouraging to see from these data that serious complications from RSV can be reduced in healthy preterm infants” said John Shiver, Senior Vice President, Global Research and Development, Sanofi Pasteur. “Most babies who are hospitalised from RSV are otherwise healthy with no prior complications,2 but currently these infants have no approved preventative option to protect them.”
RSV is a common, contagious, seasonal virus that infects the respiratory tract.2 RSV infection can cause a range of symptoms, from mild cold-like symptoms through to severe breathing difficulty.2 It is a leading cause of bronchiolitis and pneumonia in infants and young children resulting in approximately 30,000 hospital admissions of children under 5 in the UK every year, of which 6% result in admission to intensive care.2 Most of these admissions are in otherwise healthy babies.2 By the age of 2, almost all infants will have been exposed to RSV.3
Nirsevimab Clinical Trials
The Phase 2b study was conducted by AstraZeneca at 164 sites in 23 countries.1 Healthy preterm infants of 29–35 weeks’ gestation were randomised (2:1) to receive a single intramuscular injection of nirsevimab or placebo. Between November 2016 and December 2017, 1447 infants were dosed (nirsevimab, n=966; placebo, n=481) at the RSV season start.1
In July 2019, Sanofi and AstraZeneca initiated pivotal Phase 3 and Phase 2/3 trials to measure the safety and efficacy of nirsevimab to prevent LRTI caused by RSV in full-term, healthy late preterm and high-risk babies.4,5 The trials will be conducted in more than 350 sites across Northern and Southern Hemispheres.
The full results of the Phase 3 and Phase 2/3 trials are anticipated in 2023.
Nirsevimab is a passive immunisation. Passive immunisations involve delivering an antibody directly as opposed to active immunisations, which induce an antibody response from the immune system. Passive immunisation can offer immediate protection.6 Nirsevimab is not yet licenced.
In March 2017, AstraZeneca and Sanofi Pasteur announced an agreement to develop and commercialise nirsevimab jointly. Under the terms of the agreement, AstraZeneca leads all development activity through initial approvals and retains manufacturing activities and Sanofi Pasteur will lead commercialisation activities. In February 2019, AstraZeneca and Sanofi Pasteur’s nirsevimab received Breakthrough Therapy Designation from the US Food and Drug Administration and was granted access to the PRIority MEdicines (PRIME) scheme by the European Medicines Agency.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
1 Griffin MP, MD et al. (2019). Single Dose Nirsevimab for Prevention of RSV Disease in Preterm Infants. New England Journal of Medicine. Manuscript submitted for publication.
2 Vaccine Knowledge Project. Respiratory Syncytial Virus (RSV). https://vk.ovg.ox.ac.uk/vk/rsv Accessed July 2020
3 NHS. Bronchiolitis. https://www.nhs.uk/conditions/bronchiolitis/ Accessed July 2020
4 Clinicaltrials.gov. A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants (MELODY).
https://clinicaltrials.gov/ct2/show/NCT03979313. Accessed November 2019.
5 Clinicaltrials.gov. A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus (RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children. https://clinicaltrials.gov/ct2/show/NCT03959488. Accessed July 2020.
6 “Vaccines & Immunizations.” Centers for Disease Control and Prevention. August 18, 2017. https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm Accessed July 2020
Job code: MAT-GB-2001339 (v1.0)
Date of preparation: July 2020